CoAg Title:	Enhancing STI and Sexual Health Clini
CoAg Number:	RFA PS23-0011
Agency:	
Funded for Strategy C?	
Reporting Period:	
Date completed:	

Click a named tab at the bottom of the workbook to jump to the corresp

Instructions:

Please use this template to submit performance measures for **ESSHCI Activities.** This template will be completed twice a year, within the coag period.

Please refer to the performance measures guidance document for additional information an Definitions for some measures are also included in footnotes, annotated by numbers, at the breporting template.

If you need assistance or have ANY questions about completing this template, please send an

Notes on Data Entry:

All unshaded cells are available for user input.

Drop-down lists included in the worksheets will be identifiable through a downward arrow tha Gray cells are auto-calculated and do not require data entry. Blacked-out cells are not required and do not require data entry.

ONLY Recipients funded for strategy C are required to complement the strategy C tab. Data for recipients.

Saving and Submitting Your Work:

Please save this file as "[Agency Name]_Evaluation Report.Period[number]_Date of Submissi

To submit your report, save and upload a copy of the completed workbook ending in .xls or .xl Please send a courtesy email to your DSTDP project officer to notify them of your submission.

Relevant Links:

To find general information on using Microsoft Excel, click here: <u>Microsoft Excel Basics</u> Public reporting burden of this collection of information is estimated to average **40 hours per resp** gathering and maintaining the data needed, and completing and reviewing the collection of inform collection of information unless it displays a currently valid OMB control number. Send comments I suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road N c Infrastructure

Form Approved OMB Control No. 0920-1282 Exp. Date: 06/30/2026

onding worksheet.

d definitions for completing the template. ottom of the respective tables in this

email to your DSTDP project officer.

it appears when you select it.

or strategies A and B are required for all

on[mm.dd.yy]"

sx as a Grant Note in GrantSolutions by xxx

onse per year, including the time for reviewing instructions, searching existing data sources, ation. An agency may not conduct or sponsor, and a person is not required to respond to a regarding this burden estimate or any other aspect of this collection of information, including E, MS D-74, Atlanta, Georgia 30333; Attn: OMB-PRA (0920-1282).

Community Engagement and Pai

Aggregate Data Tables for PM-1 - 5

Та				
Ta	h	0	л	1
- u		е,	н	

For each type of engagement with your community advisory group, please enter the nutritis reporting period (*PM-1a*, *PM-1b*)

Type of engagements with community advisory group	Number of engagements with community advisory group
¹ Regular, In-person meetings	
² Regular, Virtual meetings	
³ Hybrid meetings	
^₄ Listening sessions	
⁵ Surveys	
⁶ Focused discussion groups	
Other (Please specify)	

Table A2.

Please provide the total and representative numbers of your community advisory grou

Gray cells: Auto-calculated and do not represent a re		
Total number of community advisory group members		
Number of community advisory group members that identify as belonging to priority population(s) your clinic(s) serves.		
Proportion of community advisory group representing priority population(s) served by the clinic.	% Auto-Calculate	

Please provide a summary of the actionable, community-informed, clinic-level plan developed, with input from the community advisory group, to increase access to quality comprehensive sexual health services in your clinic.

The description should include how your clinic involved and incorporated your community advisory group in developing the actionable clinic-level plan.

Table A3.

For each type of community partnership, please enter the number of partners that coll this reporting period (*PM-4a, 4b & 5*)

Type of community partners engaging in STI prevention collaboration	Number of community partners engaging in STI prevention collaboration
STI Clinics	
Clinics (Other)	
Hospitals	
Community-based organizations	
Faith-based organizations	
Academic institutions	
Pharmacies	
Other (Please specify)	
Please describe the partnerships and activities conducted to address STIs. Including a description of any assessment(s) conducted and outcomes achieved for the clinic-level plan.	
Please provide details outlining each partner's role in the actionable clinic-level plan.	Name of partner

Are there missing/unavailable data for any performance measures in the table(s) above?

Please explain the issues with the missing data, including variable names, and your plans to enhance the completeness of your data (if applicable).

1 Regular, In-person meetings: Scheduled/standing meetings where most attendees were in-person in one m 2 Regular, Virtual meetings: Scheduled/standing meetings taking place in a virtual meeting room such as, Zo 3 Hybrid Meetings: Regular meetings hosted simultaneously in an in-person location and a virtual meeting/v 4 Listening sessions: Gathering hosted to garner feedback on one or more issues related to the project, wheth 5 Surveys: questionnaire administered to solicit responses to questions related to the project; either web-bas 6 Focused discussion groups: Gathering hosted for an interactive discussion on a specific topic, related to the

rtnerships

umber of times each engagement occurred in

Optional Field

Enter text specifying the type(s) of engagement with the community advisory group

p members (**PM-2 & 3**)

orting burden

laborated on STI prevention with your clinic, in

Optional Field

Enter text specifying the type(s) of community partner

Level of previous partnership	Type of Partner	If "Other," please
(Select dropdown)	(Select dropdown)	specify.

Data Quality

eeting place.
om, Microsoft Teams, Google meet etc.
ideo-conferencing platform.
her taking place in-person or virtually.
ed or paper format
project, whether taking place in-person or virtually.

What role does this partner play? What type of services do they provide?	How will this partner contribute to the clinic-level plan? How will this partnership help your clinic reach/engage priority population(s)?

Sexual Health Services and Patier

Aggregate Data Tables for PM-7, 10, 18

Gray cells: Auto-calculated and do not represent a reporting burden

Table B1: Patient Satisfaction with Clinic SPlease enter data summarizing results from the				
Survey Question	0		1	
Q1: Using a rating of 0 to 5, where 0 is the worst clinical care and 5 is the best clinical care, how would you rate the STI care you received in today's visit?	Ν	%	Ν	%
	Very poor		Poor	
Q2: I would describe my overall experience during the clinic visit as:	Ν	%	Ν	%

Table B2: Providing Comprehensive Sexual Health Se		
Performance Measure		
Please describe the strategies developed to improve clinic systems for referrals, lab systems, linkages to care, treatment, and/or record keeping. Description should include clinical services, laboratory services, staffing strategy, and clinical training plans.		

Please describe the formal linkage agreements established with community partners collaborating for sexual health and co-occuring conditions.

	Data Quality
Are there missing/unavailable data for any performance measures in the table(s) above?	
Please explain the issues with the missing data, including variables names, and your plans to enhance the completeness of your data (if applicable).	

nt Satisfaction

ervices a CDC Pati	a nd STI Ca ent Satisfa	re. (PM 11) action Meas	ures.				
	2	3		2	ł	1	5
N	%	Ν	%	Ν	%	Ν	%
F	air	Goo	od	Very	Good		
Ν	%	Ν	%	Ν	%		

rvices (PM 7 & 18)

Data Fields



Sexual Hea

Aggregate Data Tables for PM-8 & 9

Black-out cells: Are not required for those measures and do not represent a repor

		Table B3. Persons Served and
		Number of Unique Persons Served ¹
	Total	
Age Group)	
<15 Yea	ars	
15-19 Y	/ears	
20-29 Y	/ears	
30-65 Y	/ears	
≥ 66 Ye		
⁵Unkno	own	
Gender		
Male		
Female		
	ender , Male to Female	
Transge	ender, Female to Male	
	ender, Not Specified	
⁵Unkno	own	
Gender of	Sex Partners	
Men w	ho have sex with only men (MSM)	
Womeı (WSW)	n who have sex with only women	
Sex wit	h both genders	
Sex wit	h opposite gender	
Other		
⁵Unkno	own	
Race and I	Ethnicity	
Hispan	ic or Latino	
<u>م</u> A	merican Indian or Alaska Native	
A ati	sian	
ъ В	lack or African American	
Not Hispanic or Latino	lative Hawaiian or Pacific Islander	
× Hi	Vhite	
ĭ ĭ №	1ore than one race selected	

5Unknown	
Population Groups	
Persons who inject drugs/Persons with substance use disorders	
Women of reproductive age (15-49 years)	
Persons experiencing homelessness	
Sex workers	
Insurance Status	
^é Private	
⁷ Public	
³ Uninsured	
⁵Unknown	

Are there missing/unavailable data for any performance measures in the table(s) above?	
Please explain the issues with the missing data, including variable names, and your plans to enhance the completeness of your data (if applicable).	

1 This is the number of UNIQUE people who received ANY sexual health services an people tested, screened, diagnosed, and/or treated or linked to care. The number of people who received preventive services should be a subset and c For unavailable or missing values, please enter the applicable numbers in the 'ur

- 2 This is the number of people who received PrEP for HIV, in the specified reporting may have discontinued by the end of the reporting period. The number of people who received preventive services should be a subset and c For unavailable or missing values, please enter the applicable numbers in the 'ur
- ³ This is the number of people who received nPEP for HIV, in the specified reportin, may have discontinued by the end of the reporting period. The number of people For unavailable or missing values, please enter the applicable numbers in the 'ur
- ⁴ This is the number of people who received DoxyPEP for bacterial STIs, in the spec received it once and may have discontinued by the end of the reporting period. For unavailable or missing values, please enter the applicable numbers in the 'ur
- ⁵ Unknown values for which the stratified data is missing or unavailable, e.g., nur

6 Private insurance includes plans provided through an employer or union, purchas

7 Public insurance includes plans funded by government at the federal, state, or lo

8 Uninsured includes persons not covered under any health insurance.

Ith Services- Prevention

ting burden

Receiving Biomedical HIV and STI Prevention Services				
Number of Persons Who Received HIV PrEP ²	Number of Persons Who Received HIV nPEP ³	Number of Persons Who Received Doxy PEP for Bacterial STIs⁴		

Data Quality

t your clinic in the specified reporting period. The number of people provided sexual health services should include

annot be greater than the number of people served. hknown' fields.

3 period. Count all persons who received one or more prescriptions for PrEP, including those who received it once and

annot be greater than the number of people served. hknown' fields.

g period. Count all persons who received one or more prescriptions for nPEP, including those who received it once and ? who received preventive services should be a subset and cannot be greater than the number of people served. nknown' fields.

:ified reporting period. Count all persons who received one or more prescriptions for DoxyPEP, including those who

ıknown' fields.

ibers of people for whom their age groups are identified.

sed by an individual, TRICARE, or other military coverage. cal level. E.g., Medicaid, Medicare, Indian Health Service.



Aggregate Data Tables for PM-12, 13, 14

Black-out cells: Are not required for those measures and do not represent a reporting burden

Table B4. Pers				
	Sypl	Syphilis		
	Number of Persons Tested ¹	Number of New Diagnosis ²	Number of Persons Tested ¹	
Total				
Symptom Status				
⁴Symptomatic (Tested)				
⁵ Asymptomatic (Screened)				
۵Unknown				
Disease Stage				
Primary				
Secondary				
Early Latent (EL)				
Late Latent (LLS)				
Neurosyphilis				
6Unknown				
Anatomic Site				
Pharyngeal				
Rectal	_			
Urogenital				
6Unknown				
Age Group				
<15 Years				
15-19 Years				
20-29 Years				
30-65 Years				
≥ 66 Years				
۵Unknown				
Gender				
Male				
Female				
Transgender, Male to Female				
Transgender, Female to Male				

Trar	nsgender, Not Specified			
Unkno	wn			
Gender	r of Sex Partners			
Mer	n who have sex with only men (MSM)			
Wor (WS	men who have sex with only women W)			
Sex	with both genders			
Sex	with opposite gender			
Oth	er			
Unkno	wn			
Race ar	nd Ethnicity		_	
Hisp	panic or Latino			
ou	American Indian or Alaska Native			
r Lati	Asian			
ic o	Black or African American			
Not Hispanic or Latino	Native Hawaiian or Pacific Islander			
Not	White			
	More than one race selected			
Unkno	wn			
Popula	tion Groups			
Pers subs	sons who inject drugs/Persons with stance use disorders			
Wor year	men of reproductive age (15-49 rs)			
Pers	sons experiencing homelessness			
Sex	workers			
		<u>I</u>	1	l

Are there missing/unavailable data for any performance measures in the table(s) above?	
Please explain the issues with the missing data, including variable names, and your plans to enhance the completeness of your data (if applicable).	

- ¹ This is the number of people who were tested for: Syphilis, Gonorrhea, Chlamydia, Mpox, and HIV in the spec For HIV, please include persons previously known or reported to be HIV positive, e.g., persons tested for confi The number of people receiving preventive services should be a subset of, and cannot be greater than, the nu
- ² This is the number of new STI cases identified: Syphilis, Gonorrhea, Chlamydia, and Mpox, in the specified rep. Please count only persons who had a positive test AND confirmed clinical diagnosis. New STI cases are the numbers of people who, at minimum, test positive after being tested in the specified re applicable numbers in the 'unknown' fields.
- ³ This is the number of persons that are newly diagnosed and were not tested and diagnosed in a previous reponent New HIV cases are the numbers of people who, at minimum, test positive after being tested in the specified reponent applicable numbers in the 'unknown' fields.

Symptom Status: Refers to the number of persons screened, tested, and/or diagnosed due to the presence or patient presenting with no throat or rectal symptoms but with urethral discharge, testing negative after uret gonorrhea/chlamydia screening, should be counted as symptomatic with reference to the gonorrhea test.)

- 4 Symptomatic (Tested): Number of persons presenting with symptoms and tested for listed STIs and/or HIV, a
- 5 Asymptomatic (Screened): Number of persons with no symptoms and thus screened for possible Syphilis, Gon
- 6 Unknown values for which the stratified data is missing or unavailable, e.g., numbers of people for whom the

Testing and Diagnosis

ydia	Gonorrhea		Мрох		н
	Gonorrnea				
Number of New Diagnosis ²	Number of Persons Tested ¹	Number of New Diagnosis ²	Number of Persons Tested ¹	Number of New Diagnosis ²	Number of Persons Tested ¹
	11		11		1

Data Quality

ified reporting period.

imation prior to initiating treatment, in each reporting period. Imber of persons served. For unavailable or missing values, please enter the applicable numbers in the 'unknown' fields.

porting period. This may include cases diagnosed in any previous reporting period and reinfected, then diagnosed in this reporting period.

porting period, and should not be greater than the number of people tested. For unavailable or missing values, please enter the

orting period. eporting period, and should not be greater than the number of people tested. For unavailable or missing values, please enter the

[•] absence of symptoms at the time of patient visit. (For example, a hral testing and positive for pharyngeal gonorrhea, after a 3-site

t time of visit.

orrhea, Chlamydia, Mpox, and/or HIV, at time of visit.

ir age groups are identified.





STI/HIV Treat

Aggregate Data Tables for PM-15, 16 & 17

Black-out cells: Are not required for those measures and do not represen Gray cells: Auto-calculated and do not represent a reporting burden

	Table B5. Persons Treat alues for the number of or the number of new Sy
	Syphilis
Number of new cases treated	Ν
Number of new persons testing positive for HIV initiated on ART	
¹ Number of new cases referred to or <u>offered</u> partner services	Ν
% of New Cases Treated/Initated on ART	%
% of New cases referred to or <u>offered</u> partner services	%

Are there missing/unavailable data for any performance measures in the table(s) above?

Please explain the issues with the missing data, including variable names, and your plans to enhance the completeness of your data (if applicable).

¹ Partner Services are a broad array of services that should be offered to persons v Please enter the values of the total number of STI cases and persons newly diagr can include persons referred to health departments (or other health partners) fo For any disease areas for which your site/jurisdiction does not offer partner servi

ment and Partner Services

it a reporting burden

ed for STI/HIV; Persons offered Partner Services

new STI and HIV cases treated and/or initated on ART. (PM-15,16) /philis and Mpox cases interviewed and offered partner services. (PM-17)

Gonorrhea	Chlamydia	Мрох	HIV
Ν	Ν	Ν	
			Ν
Ν	Ν	Ν	Ν
%	%	%	%
%	%	%	%

Data Quality		

with STIs or HIV and their sexual or substance-use equipment (i.e., needles, syringes, etc.)-sharing partners. nosed with HIV who were referred to or offered partner services in the specified reporting period. This number r partner services.

ices, please leave blank and note this in the data quality field.

Expanded Access

Data tables for PM-19, 20 & 21

Optional strategy, only completed by select clinics

to STI Prevention Care in Syndemic Approach

cc	ccess to STI Prevention Care in a Syndemic Approach (PM-19 - 21)			
	Data Fields			